Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2014

01-12-2014 | Review

Unusual effects of GH deficiency in adults: a review about the effects of GH on skin, sleep, and coagulation

Authors: F. Tanriverdi, Z. Karaca, K. Unluhizarci, F. Kelestimur

Published in: Endocrine | Issue 3/2014

Login to get access

Abstract

Based on the literature data in the last two decades, growth hormone deficiency (GHD) in adults has been accepted as a clinical entity. Due to the presence of GH and IGF-I receptors throughout the body, the physiological effects of the GH-IGF-I axis are still under investigation. The effects of GH on skin, sleep, and coagulation parameters in adults have only been investigated in detail only in the recent years. In this review, our aim was to summarize the literature regarding the effects of GHD and GH replacement treatment on the skin, sleep, and coagulation parameters in adults.
Literature
1.
R.C. Cuneo, F. Salomon, G.A. McGauley, P.H. Sonksen, The growth hormone deficiency syndrome in adults. Clin. Endocrinol. (Oxf.) 37, 387–397 (1992)
2.
G. Amato, C. Carella, S. Fazio, G. La Montagna, A. Cittadini, D. Sabatini, C. Marciano-Mone, L. Sacca, A. Bellastella, Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J. Clin. Endocrinol. Metab. 77, 1671–1676 (1993)PubMed
3.
B.A. Bengtsson, S. Eden, L. Lonn, H. Kvist, A. Stokland, G. Lindstedt, I. Bosaeus, J. Tolli, L. Sjostrom, O.G. Isaksson, Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76, 309–317 (1993)PubMed
4.
C. Gazzaruso, M. Gola, I. Karamouzis, R. Giubbini, A. Giustina, Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH—an update. J. Clin. Endocrinol. Metab. 99, 18–29 (2014)PubMed
5.
M. Gola, S. Bonadonna, M. Doga, A. Giustina, Clinical review: growth hormone and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 90, 1864–1870 (2005)PubMed
6.
M. Gola, A. Giustina, Growth hormone deficiency and cardiovascular risk: do we need additional markers? Endocrine 42, 240–242 (2012)PubMed
7.
L. Li, W. Ren, J. Li, J. Liu, L. Wang, X. Zheng, D. Liu, S. Li, R. Souvenir, J. Tang, Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency. Endocrine 42, 375–381 (2012)PubMed
8.
H. de Boer, G.J. Blok, H.J. Voerman, M. Phillips, J.A. Schouten, Serum lipid levels in growth hormone-deficient men. Metabolism 43, 199–203 (1994)PubMed
9.
F. Tanriverdi, K. Unluhizarci, M. Kula, M. Guven, F. Bayram, F. Kelestimur, Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan’s syndrome. Growth Horm. IGF Res. 15, 231–237 (2005)PubMed
10.
F. Tanriverdi, N.K. Eryol, H. Atmaca, K. Unluhizarci, I. Ozdogru, I. Sarikaya, F. Bayram, F. Kelestimur, The effects of 12 months of growth hormone replacement therapy on cardiac autonomic tone in adults with growth hormone deficiency. Clin. Endocrinol. (Oxf.) 62, 706–712 (2005)
11.
V. Ekbote, A. Khadilkar, S. Chiplonkar, Z. Mughal, V. Khadilkar, Enhanced effect of zinc and calcium supplementation on bone status in growth hormone-deficient children treated with growth hormone: a pilot randomized controlled trial. Endocrine 43, 686–695 (2013)PubMed
12.
A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)PubMedCentralPubMed
13.
G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)PubMed
14.
F. Prodam, G. Aimaretti, Could zinc supplementation improve bone status in growth hormone (GH) deficient children? Endocrine 43, 467–468 (2013)PubMed
15.
J. Gibney, J.D. Wallace, T. Spinks, L. Schnorr, A. Ranicar, R.C. Cuneo, S. Lockhart, K.G. Burnand, F. Salomon, P.H. Sonksen, D. Russell-Jones, The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 84, 2596–2602 (1999)PubMed
16.
A. Slominski, J. Wortsman, Neuroendocrinology of the skin. Endocr. Rev. 21, 457–487 (2000)PubMed
17.
18.
H.L. Sheehan, Postpartum necrosis of the anterior pituitary. J. Pathol. 45, 189–214 (1937)
19.
H.J. Schneider, G. Aimaretti, I. Kreitschmann-Andermahr, G.K. Stalla, E. Ghigo, Hypopituitarism. Lancet 369, 1461–1470 (2007)PubMed
20.
F. Tanriverdi, A. De Bellis, H. Ulutabanca, A. Bizzarro, A.A. Sinisi, G. Bellastella, P.V. Amoresano, M.L. Dalla, A. Selcuklu, K. Unluhizarci, F.F. Casanueva, F. Kelestimur, A five year prospective investigation of anterior pituitary function after traumatic brain injury: is hypopituitarism long-term after head trauma associated with autoimmunity? J. Neurotrauma 30, 1426–1433 (2013)PubMed
21.
P.E. Lobie, W. Breipohl, D.T. Lincoln, J. Garcia-Aragon, M.J. Waters, Localization of the growth hormone receptor/binding protein in skin. J. Endocrinol. 126, 467–471 (1990)PubMed
22.
S.R. Oakes, K.M. Haynes, M.J. Waters, A.C. Herington, G.A. Werther, Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts. J. Clin. Endocrinol. Metab. 75, 1368–1373 (1992)PubMed
23.
J.A. Batch, F.A. Mercuri, S.R. Edmondson, G.A. Werther, Localization of messenger ribonucleic acid for insulin-like growth factor-binding proteins in human skin by in situ hybridization. J. Clin. Endocrinol. Metab. 79, 1444–1449 (1994)PubMed
24.
A. Tavakkol, J.T. Elder, C.E. Griffiths, K.D. Cooper, H. Talwar, G.J. Fisher, K.M. Keane, S.K. Foltin, J.J. Voorhees, Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin. J. Invest. Dermatol. 99, 343–349 (1992)PubMed
25.
M. Borlu, Z. Karaca, H. Yildiz, F. Tanriverdi, B. Demirel, G. Elbuken, I. Cakir, H.S. Dokmetas, R. Colak, K. Unluhizarci, F. Kelestimur, Acromegaly is associated with decreased skin transepidermal water loss and temperature, and increased skin pH and sebum secretion partially reversible after treatment. Growth Horm. IGF Res. 22, 82–86 (2012)PubMed
26.
A. Jadresic, L.M. Banks, D.F. Child, L. Diamant, F.H. Doyle, T.R. Fraser, G.F. Joplin, The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q. J. Med. 51, 189–204 (1982)PubMed
27.
J.D. Nabarro, Acromegaly. Clin. Endocrinol. (Oxf.) 26, 481–512 (1987)
28.
P.V. Carroll, E.R. Christ, B.A. Bengtsson, L. Carlsson, J.S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, P.H. Sonksen, T. Tanaka, M. Thorne, Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83, 382–395 (1998)PubMed
29.
S.A. Pedersen, K. Welling, K.F. Michaelsen, J.O. Jorgensen, J.S. Christiansen, N.E. Skakkebaek, Reduced sweating in adults with growth hormone deficiency. Lancet 2, 681–682 (1989)PubMed
30.
K. Main, K.O. Nilsson, N.E. Skakkebaek, Influence of sex and growth hormone deficiency on sweating. Scand. J. Clin. Lab. Invest. 51, 475–480 (1991)PubMed
31.
K.M. Main, D.A. Price, M.O. Savage, N.E. Skakkebae, Decreased sweating in seven patients with Laron syndrome. J. Clin. Endocrinol. Metab. 77, 821–823 (1993)PubMed
32.
A. Juul, A. Behrenscheer, T. Tims, B. Nielsen, J. Halkjaer-Kristensen, N.E. Skakkebaek, Impaired thermoregulation in adults with growth hormone deficiency during heat exposure and exercise. Clin. Endocrinol. (Oxf.) 38, 237–244 (1993)
33.
A. Juul, N. Hjortskov, L.T. Jepsen, B. Nielsen, J. Halkjaer-Kristensen, N. Vahl, J.O. Jorgensen, J.S. Christiansen, N.E. Skakkebaek, Growth hormone deficiency and hyperthermia during exercise: a controlled study of sixteen GH-deficient patients. J. Clin. Endocrinol. Metab. 80, 3335–3340 (1995)PubMed
34.
J.C. Ives, M. Alderman, S.E. Stred, Hypopituitarism after multiple concussions: a retrospective case study in an adolescent male. J. Athl. Train. 42, 431–439 (2007)PubMedCentralPubMed
35.
F. Tanriverdi, K. Unluhizarci, B. Coksevim, A. Selcuklu, F.F. Casanueva, F. Kelestimur, Kickboxing sport as a new cause of traumatic brain injury-mediated hypopituitarism. Clin. Endocrinol. (Oxf.) 66, 360–366 (2007)
36.
F. Tanriverdi, K. Unluhizarci, I. Kocyigit, I.S. Tuna, Z. Karaca, A.C. Durak, A. Selcuklu, F.F. Casanueva, F. Kelestimur, Brief communication: pituitary volume and function in competing and retired male boxers. Ann. Intern. Med. 148, 827–831 (2008)PubMed
37.
S.B. Sneppen, K.M. Main, A. Juul, L.M. Pedersen, L.O. Kristensen, N.E. Skakkebaek, U. Feldt-Rasmussen, Sweat secretion rates in growth hormone disorders. Clin. Endocrinol. (Oxf.) 53, 601–608 (2000)
38.
R. Choudhry, M.B. Hodgins, T.H. Van der Kwast, A.O. Brinkmann, W.J. Boersma, Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J. Endocrinol. 133, 467–475 (1992)PubMed
39.
K. Sato, W.H. Kang, K. Saga, K.T. Sato, Biology of sweat glands and their disorders. I. Normal sweat gland function. J. Am. Acad. Dermatol. 20, 537–563 (1989)PubMed
40.
J.M. Lundberg, B. Hedlund, T. Bartfai, Vasoactive intestinal polypeptide enhances muscarinic ligand binding in cat submandibular salivary gland. Nature 295, 147–149 (1982)PubMed
41.
W. Hasan, T. Cowen, P.S. Barnett, E. Elliot, P. Coskeran, P.M. Bouloux, The sweating apparatus in growth hormone deficiency, following treatment with r-hGH and in acromegaly. Auton. Neurosci. 89, 100–109 (2001)PubMed
42.
M. Lange, J. Thulesen, U. Feldt-Rasmussen, N.E. Skakkebaek, N. Vahl, J.O. Jorgensen, J.S. Christiansen, S.S. Poulsen, S.B. Sneppen, A. Juul, Skin morphological changes in growth hormone deficiency and acromegaly. Eur. J. Endocrinol. 145, 147–153 (2001)PubMed
43.
D. Deplewski, R.L. Rosenfield, Role of hormones in pilosebaceous unit development. Endocr. Rev. 21, 363–392 (2000)PubMed
44.
F. Kelestimur, GH deficiency and the degree of hypopituitarism. Clin. Endocrinol. (Oxf.) 42, 443–444 (1995)
45.
M. Borlu, F. Tanriverdi, C.A. Koc, K. Unluhizarci, S. Utas, F. Kelestimur, The effects of severe growth hormone deficiency on the skin of patients with Sheehan’s syndrome. J. Eur. Acad. Dermatol. Venereol. 21, 199–204 (2007)PubMed
46.
F. Tanriverdi, M. Borlu, H. Atmaca, C.A. Koc, K. Unluhizarci, S. Utas, F. Kelestimur, Investigation of the skin characteristics in patients with severe GH deficiency and the effects of 6 months of GH replacement therapy: a randomized placebo controlled study. Clin. Endocrinol. (Oxf.) 65, 579–585 (2006)
47.
D. Deplewski, R.L. Rosenfield, Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology 140, 4089–4094 (1999)PubMed
48.
A.R. Buz’Zard, Q. Peng, B.H. Lau, Kyolic and Pycnogenol increase human growth hormone secretion in genetically-engineered keratinocytes. Growth Horm. IGF Res. 12, 34–40 (2002)PubMed
49.
G. Broniarczyk-Dyla, E. Joss-Wichman, Ageing of the skin during menopause. J. Eur. Acad. Dermatol. Venereol. 15, 494–495 (2001)PubMed
50.
D.R. Clemmons, M. Molitch, A.R. Hoffman, A. Klibanski, C.J. Strasburger, D.L. Kleinberg, K. Ho, S.M. Webb, M.D. Bronstein, R. Bouillon, A. Ben Shlomo, A.H. Hamrahian, P. Chanson, A.L. Barkan, G.R. Merriam, M.R. Blackman, R. Salvatori, Growth hormone should be used only for approved indications. J. Clin. Endocrinol. Metab. 99, 409–411 (2014)PubMed
51.
S.R. Edmondson, S.P. Thumiger, G.A. Werther, C.J. Wraight, Epidermal homeostasis: the role of the growth hormone and insulin-like growth factor systems. Endocr. Rev. 24, 737–764 (2003)PubMed
52.
A. Steiger, Sleep, endocrinology. J. Intern. Med. 254, 13–22 (2003)PubMed
53.
E. Van Cauter, L. Plat, G. Copinschi, Interrelations between sleep and the somatotropic axis. Sleep 21, 553–566 (1998)PubMed
54.
C. Gronfier, G. Brandenberger, Ultradian rhythms in pituitary and adrenal hormones: their relations to sleep. Sleep Med. Rev. 2, 17–29 (1998)PubMed
55.
K. Spiegel, R. Leproult, E.F. Colecchia, M. L’Hermite-Baleriaux, Z. Nie, G. Copinschi, E. Van Cauter, Adaptation of the 24-h growth hormone profile to a state of sleep debt. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R874–R883 (2000)PubMed
56.
E. Van Cauter, A. Caufriez, M. Kerkhofs, A. Van Onderbergen, M.O. Thorner, G. Copinschi, Sleep, awakenings, and insulin-like growth factor-I modulate the growth hormone (GH) secretory response to GH-releasing hormone. J. Clin. Endocrinol. Metab. 74, 1451–1459 (1992)PubMed
57.
E.D. Weitzman, Biologic rhythms and hormone secretion patterns. Hosp. Pract. 11, 79–86 (1976)PubMed
58.
F. Obal Jr, R. Floyd, L. Kapas, B. Bodosi, J.M. Krueger, Effects of systemic GHRH on sleep in intact and hypophysectomized rats. Am. J. Physiol. 270, E230–E237 (1996)PubMed
59.
L. Marshall, M. Molle, G. Boschen, A. Steiger, H.L. Fehm, J. Born, Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration in promoting slow-wave sleep (SWS). J. Clin. Endocrinol. Metab. 81, 1009–1013 (1996)PubMed
60.
A. Steiger, J. Guldner, U. Hemmeter, B. Rothe, K. Wiedemann, F. Holsboer, Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology 56, 566–573 (1992)PubMed
61.
F. Obal Jr, P. Alfoldi, A.B. Cady, L. Johannsen, G. Sary, J.M. Krueger, Growth hormone-releasing factor enhances sleep in rats and rabbits. Am. J. Physiol. 255, R310–R316 (1988)PubMed
62.
J. Zhang, F. Obal Jr, T. Zheng, J. Fang, P. Taishi, J.M. Krueger, Intrapreoptic microinjection of GHRH or its antagonist alters sleep in rats. J. Neurosci. 19, 2187–2194 (1999)PubMed
63.
M. Kerkhofs, E. Van Cauter, A. Van Onderbergen, A. Caufriez, M.O. Thorner, G. Copinschi, Sleep-promoting effects of growth hormone-releasing hormone in normal men. Am. J. Physiol. 264, E594–E598 (1993)PubMed
64.
B. Perras, L. Marshall, G. Kohler, J. Born, H.L. Fehm, Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuroendocrinology 24, 743–757 (1999)PubMed
65.
S. Mathias, K. Held, M. Ising, J.C. Weikel, A. Yassouridis, A. Steiger, Systemic growth hormone-releasing hormone (GHRH) impairs sleep in healthy young women. Psychoneuroendocrinology 32, 1021–1027 (2007)PubMed
66.
G. Copinschi, A. Nedeltcheva, R. Leproult, L.L. Morselli, K. Spiegel, E. Martino, J.J. Legros, R.E. Weiss, J. Mockel, E. Van Cauter, Sleep disturbances, daytime sleepiness, and quality of life in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. 95, 2195–2202 (2010)PubMedCentralPubMed
67.
J. Zhang, F. Obal Jr, J. Fang, B.J. Collins, J.M. Krueger, Non-rapid eye movement sleep is suppressed in transgenic mice with a deficiency in the somatotropic system. Neurosci. Lett. 220, 97–100 (1996)PubMed
68.
C. Astrom, Interaction between sleep and growth hormone. Evaluated by manual polysomnography and automatic power spectrum analysis. Acta Neurol. Scand. 92, 281–296 (1995)PubMed
69.
W.B. Mendelson, S. Slater, P. Gold, J.C. Gillin, The effect of growth hormone administration on human sleep: a dose-response study. Biol. Psychiatry 15, 613–618 (1980)PubMed
70.
C. Astrom, J. Lindholm, Growth hormone-deficient young adults have decreased deep sleep. Neuroendocrinology 51, 82–84 (1990)PubMed
71.
S. Ismailogullari, F. Tanriverdi, F. Kelestimur, M. Aksu, Sleep architecture in Sheehan’s syndrome before and 6 months after growth hormone replacement therapy. Psychoneuroendocrinology 34, 212–219 (2009)PubMed
72.
L.L. Morselli, A. Nedeltcheva, R. Leproult, K. Spiegel, E. Martino, J.J. Legros, R.E. Weiss, J. Mockel, E. Van Cauter, G. Copinschi, Impact of GH replacement therapy on sleep in adult patients with GH deficiency of pituitary origin. Eur. J. Endocrinol. 168, 763–770 (2013)PubMed
73.
W. Nolte, C. Radisch, A. Rodenbeck, J. Wiltfang, M. Hufner, Polysomnographic findings in five adult patients with pituitary insufficiency before and after cessation of human growth hormone replacement therapy. Clin. Endocrinol. (Oxf.) 56, 805–810 (2002)
74.
Y. Peker, J. Svensson, J. Hedner, L. Grote, G. Johannsson, Sleep apnoea and quality of life in growth hormone (GH)-deficient adults before and after 6 months of GH replacement therapy. Clin. Endocrinol. (Oxf.) 65, 98–105 (2006)
75.
H.J. Schneider, H. Oertel, H. Murck, T. Pollmacher, G.K. Stalla, A. Steiger, Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement. Psychoneuroendocrinology 30, 29–37 (2005)PubMed
76.
B. Bulow, L. Hagmar, Z. Mikoczy, C.H. Nordstrom, E.M. Erfurth, Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. (Oxf.) 46, 75–81 (1997)
77.
B. Bulow, L. Hagmar, J. Eskilsson, E.M. Erfurth, Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J. Clin. Endocrinol. Metab. 85, 574–584 (2000)PubMed
78.
E.M. Erfurth, B. Bulow, J. Eskilsson, L. Hagmar, High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: preliminary results. Growth Horm. IGF Res. 9(Suppl A), 21–24 (1999)PubMed
79.
T. Rosen, B.A. Bengtsson, Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336, 285–288 (1990)PubMed
80.
A. Sartorio, M. Cattaneo, P. Bucciarelli, B. Bottasso, S. Porretti, P. Epaminonda, G. Faglia, M. Arosio, Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp. Clin. Endocrinol. Diabetes 108, 486–492 (2000)PubMed
81.
J. Guevara-Aguirre, P. Balasubramanian, M. Guevara-Aguirre, M. Wei, F. Madia, C.W. Cheng, D. Hwang, A. Martin-Montalvo, J. Saavedra, S. Ingles, R. de Cabo, P. Cohen, V.D. Longo, Growth hormone receptor deficiency ıs associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 16, 70ra13 (2011)
82.
M.H. Aguiar-Oliveira, F.T. Oliveira, R.M. Pereira, C.R. Oliveira, A. Blackford, E.H. Valenca, E.G. Santos, M.B. Gois-Junior, R.A. Meneguz-Moreno, V.P. Araujo, L.A. Oliveira-Neto, T.F. Lopes, E.O. Rodrigues, L.A. Porto, I.P. Oliveira, E.V. Melo, M. Martari, R. Salvatori, Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. J. Clin. Endocrinol. Metab. 295, 714–721 (2010)
83.
M. Franchini, G. Lippi, F. Manzato, P.P. Vescovi, G. Targher, Hemostatic abnormalities in endocrine and metabolic disorders. Eur. J. Endocrinol. 162, 439–451 (2010)PubMed
84.
F. Tanriverdi, A. Gul, I. Gul, N.K. Eryol, K. Unluhizarci, F. Kelestimur, Massive cardiac thrombosis in a patient with Sheehan’s syndrome. Endocr. J. 52, 709–714 (2005)PubMed
85.
L.S. Savendahl, K. Grankvist, K.G. Engstrom, Growth hormone deficiency impairs blood clotting and reduces factor VII coagulant activity in rat. Thromb. Haemost. 73, 626–629 (1995)PubMed
86.
P. Bubber, K.P. Singh, S. Arora, D.D. Bansal, Effect of growth hormone on fibrinolytic system in rat. Indian J. Exp. Biol. 36, 514–516 (1998)PubMed
87.
A. Hamsten, U. de Faire, G. Walldius, G. Dahlen, A. Szamosi, C. Landou, M. Blomback, B. Wiman, Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2, 3–9 (1987)PubMed
88.
W.B. Kannel, New perspectives on cardiovascular risk factors. Am. Heart J. 114, 213–219 (1987)PubMed
89.
F.B. Smith, A.J. Lee, F.G. Fowkes, J.F. Price, A. Rumley, G.D. Lowe, Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler. Thromb. Vasc. Biol. 17, 3321–3325 (1997)PubMed
90.
J.K. Devin, L.S. Blevins Jr, D.K. Verity, Q. Chen, J.R. Bloodworth Jr, J. Covington, D.E. Vaughan, Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. 92, 3633–3639 (2007)PubMed
91.
J.O. Johansson, K. Landin, L. Tengborn, T. Rosen, B.A. Bengtsson, High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler. Thromb. 14, 434–437 (1994)PubMed
92.
J. Kvasnicka, J. Marek, T. Kvasnicka, V. Weiss, M. Markova, J. Stepan, A. Umlaufova, Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clin. Endocrinol. (Oxf.) 52, 543–548 (2000)
93.
M. Margaglione, G. Cappucci, M. d’Addedda, D. Colaizzo, N. Giuliani, G. Vecchione, G. Mascolo, E. Grandone, G. Di Minno, PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler. Thromb. Vasc. Biol. 18, 562–567 (1998)PubMed
94.
M.N. Di Minno, S. Pezzullo, V. Palmieri, C. Di Somma, R. Lupoli, D. Valle, G. Lombardi, G. Di Minno, Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy: correlations with PAI-1 and t-PA plasma levels. Thromb. Res. 126, e434–e438 (2010)PubMed
95.
J.O. Johansson, K. Landin, G. Johannsson, L. Tengborn, B.A. Bengtsson, Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb. Haemost. 76, 422–428 (1996)PubMed
96.
I. Cakir, F. Tanriverdi, Z. Karaca, L. Kaynar, B. Eser, K. Unluhizarci, F. Kelestimur, Evaluation of coagulation and fibrinolytic parameters in adult onset GH deficiency and the effects of GH replacement therapy: a placebo controlled study. Growth Horm. IGF Res. 22, 17–21 (2012)PubMed
97.
D. Miljic, P. Miljic, M. Doknic, S. Pekic, M. Djurovic, M. Colovic, V. Popovic, Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient adults. Hormones (Athens) 5, 187–191 (2006)
98.
T.A. Elhadd, T.A. Abdu, J. Oxtoby, G. Kennedy, M. McLaren, R. Neary, J.J. Belch, R.N. Clayton, Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J. Clin. Endocrinol. Metab. 86, 4223–4232 (2001)PubMed
99.
J.M. Gomez, M. Sahun, R. Vila, P. Domenech, P. Catalina, J. Soler, L. Badimon, Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency. Clin. Endocrinol. (Oxf.) 64, 632–639 (2006)
100.
J.M. Gomez, M. Sahun, R. Vila, P. Domenech, P. Catalina, J. Soler, L. Badimon, Elevation of E-selectin concentrations may correlate with potential endothelial dysfunction in individuals with hypopituitarism during therapy with growth hormone. Curr. Neurovasc. Res. 4, 55–62 (2007)PubMed
101.
J.C. Smith, H.A. Lane, J. Lewis, S. Dann, J. Goodfellow, P. Collins, L.M. Evans, M.F. Scanlon, J.S. Davies, Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin. J. Clin. Endocrinol. Metab. 88, 2152–2156 (2003)PubMed
102.
S. Bergamaschi, C. Giavoli, E. Ferrante, A. Lania, R. Rusconi, A. Spada, P. Beck-Peccoz, Growth hormone replacement therapy in growth hormone deficient children and adults: effects on hemochrome. J. Endocrinol. Invest. 29, 399–404 (2006)PubMed
Metadata
Title
Unusual effects of GH deficiency in adults: a review about the effects of GH on skin, sleep, and coagulation
Authors
F. Tanriverdi
Z. Karaca
K. Unluhizarci
F. Kelestimur
Publication date
01-12-2014
Publisher
Springer US
Published in
Endocrine / Issue 3/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0276-0

Other articles of this Issue 3/2014

Endocrine 3/2014 Go to the issue

Original Article

Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells

Original Article

Assessment of early renal damage in diabetic rhesus monkeys

Pros and Cons in Endocrine Practice

Surgical treatment of prolactinomas: cons

Original Article

Comparative analysis of glucoinsulinemic markers and proinflammatory cytokines in prepubertal children born large-versus appropriate-for gestational age

Original Article

Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: an in vivo study

Original Article

Women with prolactinomas presented at the postmenopausal period
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits